Abstract: OBJECTIVE To provide the risk assessment of off-label use of bevacizumab and triamcinolone acetonide in ophthalmology. METHODS According to the retrospective study, the clinical effects and potential risk of bevacizumab and triamcinolone acetonide in ophthalmology were analyzed. RESULTS In the short term, bevacizumab and triamcinolone acetonide had remarkable clinical effects. However, there were still some potential risks. CONCLUSION To ensure the patients receive the benefits far more than the potential risks, long-term, multicenter randomized studies should be taken out with large samples in off-label use. The off-label use in ophthalmolog should be discussed about informed consent, safety and management.